Team 3 oncogenesis of cutaneous lymphomas, Translational Oncology ,
Dermatology Department, Hospital Saint-Louis, Dermatology Department Dermatology Department, vol.10, issue.11 ,
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Dermatology Department, CHU Reims Nature, vol.14, issue.403, pp.503-511, 2000. ,
Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification, British Journal of Dermatology, vol.143, issue.5, pp.1118-1123, 2012. ,
DOI : 10.1001/archderm.143.9.1144
Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era, Leukemia & Lymphoma, vol.122, issue.5, pp.1213-1222, 2015. ,
DOI : 10.1016/j.jmoldx.2012.11.006
IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials, p.3101, 2014. ,
Lenalidomide for the Treatment of B-Cell Malignancies, Journal of Clinical Oncology, vol.26, issue.9, pp.1544-1552, 2008. ,
DOI : 10.1200/JCO.2007.14.5367
Rituximab therapy in malignant lymphoma, Oncogene, vol.94, issue.25, pp.3603-3613, 2007. ,
DOI : 10.1002/cncr.11511
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-242, 2002. ,
DOI : 10.1056/NEJMoa011795
Mutations of multiple genes cause deregulation of NF-??B in diffuse large B-cell lymphoma, Nature, vol.272, issue.7247, pp.717-721, 2009. ,
DOI : 10.1038/nature07968
A Phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL, Clin Cancer Res, 2017. ,
Lenalidomide mode of action: linking bench and clinical findings Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide 24, Blood Rev, pp.13-19, 2010. ,
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Chronic Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma, pp.88-92, 2010. ,
DOI : 10.4049/jimmunol.166.3.1507
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma, Blood, vol.113, issue.24, pp.6069-6076, 2009. ,
DOI : 10.1182/blood-2009-01-199679
Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis, Int. J. Clin. Exp. Med, vol.8, pp.10705-10713, 2015. ,
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.23, issue.18, pp.4117-4126, 2005. ,
DOI : 10.1200/JCO.2005.09.131
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), European Journal of Cancer, vol.54, pp.11-17, 2016. ,
DOI : 10.1016/j.ejca.2015.10.005
MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In??Vitro and In??Vivo, MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo, pp.812-824, 2012. ,
DOI : 10.1016/j.ccr.2012.11.003
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia, Clinical Cancer Research, vol.16, issue.3, pp.1033-1041, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1837
Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab, Archives of Dermatology, vol.145, issue.3, pp.329-330, 2009. ,
DOI : 10.1001/archdermatol.2009.23
Cutaneous Lymphomas, Archives of Dermatology, vol.145, issue.6, 2009. ,
DOI : 10.1001/archdermatol.2009.117
URL : https://hal.archives-ouvertes.fr/hal-00396446
Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study, Journal of Clinical Oncology, vol.19, issue.16, pp.3602-3610, 2001. ,
DOI : 10.1200/JCO.2001.19.16.3602
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Archives of Dermatology, vol.143, issue.9, pp.1144-1150, 2007. ,
DOI : 10.1001/archderm.143.9.1144
Prise en charge des lymphomes B cutan??s??: recommandations du Groupe fran??ais d?????tude des lymphomes cutan??s, Annales de Dermatologie et de V??n??r??ologie, vol.137, issue.8-9, pp.523-531, 2010. ,
DOI : 10.1016/j.annder.2010.04.016
Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France, JAMA Dermatology, vol.150, issue.5, pp.535-541, 2014. ,
DOI : 10.1001/jamadermatol.2013.7452
Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France, JAMA Dermatology, vol.150, issue.5, pp.535-541, 2014. ,
DOI : 10.1001/jamadermatol.2013.7452
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.33, issue.25, pp.2803-2811, 2015. ,
DOI : 10.1200/JCO.2014.59.5363
Excellent outcome of immunomodulation or Bruton???s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type, Rare Tumors, vol.7, issue.4, pp.6067-2015, 2015. ,
DOI : 10.4081/rt.2015.6067
Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large Bcell lymphomas, leg type, in elderly patients, Arch. Dermatol, vol.146, pp.89-91, 2010. ,
Survival Data for 299 Patients with Primary Cutaneous Lymphomas: A Monocentre Study, Acta Dermato Venereologica, vol.91, issue.5, pp.521-525, 2011. ,
DOI : 10.2340/00015555-1112
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-282, 2004. ,
DOI : 10.1182/blood-2003-05-1545
Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo, Clinical Cancer Research, vol.20, issue.10, pp.2674-2683, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-3007
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype, Cancer, vol.13, issue.suppl 1, pp.5058-5066, 2011. ,
DOI : 10.1016/j.gde.2003.08.004
Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma, Modern Pathology, vol.19, issue.9, pp.1270-1276, 2006. ,
DOI : 10.4049/jimmunol.165.10.5462
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas, Leukemia & Lymphoma, vol.122, issue.3, pp.635-643, 2016. ,
DOI : 10.1111/j.1600-0609.1996.tb01390.x
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.19, issue.1, pp.2508-2513, 2014. ,
DOI : 10.1002/cncr.26135
Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy, Discov. Med, vol.18, pp.51-65, 2014. ,
Selective interleukin-1 receptor???associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy, The Journal of Experimental Medicine, vol.11, issue.13, pp.2189-2201, 2015. ,
DOI : 10.1016/j.ccr.2012.05.024
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma, Blood, vol.124, p.4443, 2014. ,
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC), Blood, vol.110, issue.2, pp.479-484, 2007. ,
DOI : 10.1182/blood-2006-10-054601
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination, Nature Immunology, vol.3, issue.7, pp.773-782, 2006. ,
DOI : 10.4049/jimmunol.172.9.5427
Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients, Blood, vol.106, issue.7, pp.2491-2497, 2005. ,
DOI : 10.1182/blood-2005-03-1175
Nuclear Factor-??B Pathway???Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.134, issue.1, pp.290-292, 2014. ,
DOI : 10.1038/jid.2013.265
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites, Blood Cancer Journal, vol.120, issue.9, p.139, 2013. ,
DOI : 10.1182/blood-2011-11-390989
Lymphoprolif??rations cutan??es??: proposition d???algorithmes diagnostiques ?? partir de l???exp??rience sur 2ans des r??seaux INCa (LYMPHOPATH et GFELC) sur 2760??lymphoprolif??rations cutan??es, Annales de Pathologie, vol.35, issue.2, pp.131-147, 2015. ,
DOI : 10.1016/j.annpat.2015.02.001
Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma, International Journal of Cancer, vol.104, issue.5, pp.971-979, 2006. ,
DOI : 10.4049/jimmunol.171.1.88
Targeting the Toll-like Receptor, 2013. ,
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response, British Journal of Haematology, vol.109, issue.4 Suppl. 4, pp.325-336, 2011. ,
DOI : 10.1182/blood-2006-07-038703
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?, The Oncologist, vol.21, issue.9, pp.1107-1112, 2016. ,
DOI : 10.1634/theoncologist.2016-0103
Oncogenically active MYD88 mutations in human lymphoma, Nature, vol.206, issue.7332, pp.115-119, 2011. ,
DOI : 10.1084/jem.20090528
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma, Future Oncology, vol.126, issue.23, pp.1553-1563, 2016. ,
DOI : 10.1200/JCO.2007.15.9277
Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non???Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study, Journal of Clinical Oncology, vol.33, issue.3, pp.251-257, 2015. ,
DOI : 10.1200/JCO.2014.55.5714
Analysis of the coding genome of diffuse large B-cell lymphoma, Nature Genetics, vol.96, issue.9, pp.830-837, 2011. ,
DOI : 10.1093/bioinformatics/btl646
Simultaneous Inhibition of PI3K?? and PI3K?? Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-??B and AKT, Simultaneous Inhibition of PI3K? and PI3K? Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-?B and AKT, pp.64-78, 2017. ,
DOI : 10.1016/j.ccell.2016.12.003
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial, The Lancet Oncology, vol.12, issue.5, pp.460-468, 2011. ,
DOI : 10.1016/S1470-2045(11)70069-9
High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type, JAMA Dermatology, vol.150, issue.11, pp.1173-1179, 2014. ,
DOI : 10.1001/jamadermatol.2014.821
MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.132, issue.8, pp.2118-2120, 2012. ,
DOI : 10.1038/jid.2012.102
Diagnostic and Prognostic Value of BCL2 Rearrangement in 53 Patients With Follicular Lymphoma Presenting as Primary Skin Lesions, American Journal of Clinical Pathology, vol.143, issue.3, pp.362-373, 2015. ,
DOI : 10.1309/AJCP4SUBR4NPSPTN
Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma, Modern Pathology, vol.32, pp.402-411, 2014. ,
DOI : 10.1097/DAD.0b013e3181c1195b
IRF4 Expression without IRF4 Rearrangement Is a General Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.130, issue.5, pp.1470-1472, 2010. ,
DOI : 10.1038/jid.2009.418
Diffuse large B-cell lymphoma???treatment approaches in the molecular era, Nature Reviews Clinical Oncology, vol.120, issue.1, pp.12-23, 2013. ,
DOI : 10.1038/nature09671
Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type, Annals of Hematology, vol.22, issue.7, 2014. ,
DOI : 10.1093/annonc/mdq626
Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO???EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers, Journal of Clinical Oncology, vol.25, issue.12, pp.1581-1587, 2007. ,
DOI : 10.1200/JCO.2006.09.6396
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas, Blood, vol.112, issue.5, pp.1600-1609, 2008. ,
DOI : 10.1182/blood-2008-04-152850
The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S??zary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group, British Journal of Dermatology, vol.19, issue.6, pp.1205-1211, 2007. ,
DOI : 10.1182/blood-2005-03-1175
Fine-Mapping Chromosomal Loss at 9p21: Correlation with Prognosis in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.129, issue.5, pp.1149-1155, 2009. ,
DOI : 10.1038/jid.2008.357
Temsirolimus Has Activity in Non???Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium, Journal of Clinical Oncology, vol.28, issue.31, pp.4740-4746, 2010. ,
DOI : 10.1200/JCO.2010.29.2813
Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study, Journal of Cutaneous Pathology, vol.90, issue.3, pp.227-234, 2005. ,
DOI : 10.1111/j.1365-2133.2003.05649.x
Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type, Annals of Hematology, vol.93, issue.5, pp.895-896, 2014. ,
DOI : 10.1007/s00277-013-1787-0
The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-2390, 2016. ,
DOI : 10.1182/blood-2016-01-643569
WHO classification of tumours of haematopoietic and ymphoid tissues, 2008. ,
A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer, British Journal of Cancer, vol.50, issue.6, pp.843-850, 2002. ,
DOI : 10.1038/sj.bjc.6600199
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.116-125, 2015. ,
DOI : 10.1093/annonc/mdv304
MYD88 L265P Somatic Mutation in Waldenstr??m's Macroglobulinemia, MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia, pp.826-833, 2012. ,
DOI : 10.1056/NEJMoa1200710
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells, Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells, pp.746-755, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-2317
Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group, Archives of Dermatology, vol.132, issue.11, pp.1304-1308, 1996. ,
DOI : 10.1001/archderm.132.11.1304
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial, The Lancet Oncology, vol.15, issue.7, pp.730-737, 2014. ,
DOI : 10.1016/S1470-2045(14)70191-3
somatic mutation for B cell tolerance, The Journal of Experimental Medicine, vol.2013, issue.3, pp.413-426, 2014. ,
DOI : 10.1182/blood-2012-09-454355
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, Leukemia, vol.22, issue.9, pp.1902-1909, 2013. ,
DOI : 10.1200/JCO.2005.05.1003
[Primary cutaneous diffuse large B-cell lymphoma, leg type: a study of clinicopathology, immunophenotype and gene rearrangement], Zhonghua Bing Li Xue Za Zhi, vol.44, pp.100-105, 2015. ,
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.26, issue.30, pp.4952-4957, 2008. ,
DOI : 10.1200/JCO.2007.15.3429
WHO-EORTC classification for cutaneous lymphomas, .J.L.M., 2005. WHO-EORTC classification for cutaneous lymphomas, pp.3768-3785 ,
DOI : 10.1182/blood-2004-09-3502
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer, Blood, vol.90, pp.354-371, 1997. ,
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, .M., Staudt, L.M., 2015. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, pp.922-926 ,
DOI : 10.1200/JCO.2006.09.2403
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, Annals of Oncology, vol.22, issue.7, pp.1622-1627, 2011. ,
DOI : 10.1093/annonc/mdq626
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma, Cancer Cell, vol.21, issue.6, pp.723-737 ,
DOI : 10.1016/j.ccr.2012.05.024
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression, British Journal of Haematology, vol.118, issue.Suppl. 1, pp.487-502, 2013. ,
DOI : 10.1182/blood-2011-05-356063
Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.6, pp.462-466, 2011. ,
DOI : 10.1016/j.clml.2011.02.001
Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas, Journal of Clinical Oncology, vol.24, issue.9, pp.1376-1382, 2006. ,
DOI : 10.1200/JCO.2005.03.6285
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice, Leukemia & Lymphoma, vol.17, issue.6, pp.1671-1676 ,
DOI : 10.1111/bjh.12008
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study, Leukemia & Lymphoma, vol.18, issue.1, pp.226-229, 2017. ,
DOI : 10.1002/cncr.28405
Pôle"de"Santé"PubliqueUnité"de"Soutien"Méthodologique"à"la"Recherche"clinique"et"EpidémiologiqueService"de"Dermatologie ,
Research"in"Translational"OncologyOncogénèse"des"lymphomes"cutanés' " 4 "Groupe"Français"d'étude"des"lymphomes"cutanés ,
inefficace'sur'les'19'patients'recrutés'mais'avec'un'manque'de'puissance'important.'Selon'l'approche'bayésienne,' même'avec'un'a"priori'optimiste'sur'l'efficacité'du'traitement,'l'intervalle'de'crédibilité'n'est'pas'strictement'supérieur'à'20%'après'avoir'pris'en'compte'les'données'de'l'essai.' ? Ces'deux'approches'tendent'vers'la'même'conclusion'd'efficacité'insuffisante'du'traitement.' ? En'l'absence'de'données'de'la'littérature'sur'ce'traitement'dans'des'populations'comparables,'l'analyse'bayésienne'a'permis'd'interpréter'les'résultats'suivant'différents'contextes' et'il'a'été'possible'd'utiliser'les'hypothèses'du'calcul'de'la'taille'd'étude'pour'définir'les'distributions'a'priori ,
Optimal'two5stage'designs'for'phase'II'clinical'trials, Control"Clin"Trials', vol.10, issue.1, pp.1-10, 1989. ,
Bayesian'design'and'conduct'of'phase'II'single5arm'clinical'trials'with'binary'outcomes:'a'tutorial, Contemp"Clin"Trials.', vol.29, pp.608-624, 2008. ,
A'Bayesian're5assessment'of'two'phase'II'trials'of'gemcitabine'in'metastatic'nasopharyngeal'cancer, Br"J"Cancer', vol.86, pp.843-50, 2002. ,